How Wegovy Works: Why Doctors Recommend It for Weight Managemen Wegovys active ingredient, semaglutide, is a GLP-1 receptor agonist
Of them, 20.4% had arterial hypertension, 51% had dyslipidemia, and 44.9%, 16.3% and 10.2% had diabetic retinopathy, nephropathy and neuropathy, respectively
Most reported GI events were mild to moderate in severity and predominantly occurred during the dose-escalation phase across all treatment groups (11)
Both peptides lack tumor-promoting activity in published studies, and neither affects cortisol, prolactin, or other hormonal axes
It is important to be patient and recognize that your body is simply processing the medication at a slower pace
While undergoing GLP-1induced appetite or weight shift, keep it focused and practical